Identification

Name
Trimipramine
Accession Number
DB00726  (APRD00498)
Type
Small Molecule
Groups
Approved
Description

Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]

Structure
Thumb
Synonyms
  • 10,11-dihydro-N,N,beta-Trimethyl-5H-dibenz[b,F]azepine-5-propanamine
  • 5-(gamma-dimethylamino-beta-Methylpropyl)-10,11-dihydro-5H-dibenzo[b,F]azepine
  • 5-[3-(dimethylamino)-2-Methylpropyl]-10,11-dihydro-5H-dibenz[b,F]azepine
  • beta-Methylimipramine
  • RP-7162
  • Sapilent
  • Trimeprimina
  • Trimeprimine
  • Trimeproprimine
  • Trimipramina
  • Trimipramine
  • Trimipraminum
External IDs
IF 6120 / IL 6001 / RP 7162
Product Ingredients
IngredientUNIICASInChI Key
Trimipramine maleate269K6498LD521-78-8YDGHCKHAXOUQOS-BTJKTKAUSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RhotrimineTablet100 mgOralSanofi Aventis1988-12-312007-03-29Canada
RhotrimineTablet12.5 mgOralSanofi Aventis1988-12-312006-07-28Canada
RhotrimineTablet50 mgOralSanofi Aventis1988-12-312006-07-28Canada
RhotrimineCapsule75 mgOralSanofi Aventis1988-12-312007-03-29Canada
RhotrimineTablet25 mgOralSanofi Aventis1988-12-312006-07-28Canada
SurmontilCapsule25 mg/1OralTeva Women's Health1990-09-30Not applicableUs51285 0538 02 nlmimage10 9f304fb2
SurmontilTablet25 mgOralSanofi Aventis1964-12-312006-07-28Canada
SurmontilCapsule100 mg/1OralTeva Women's Health1990-09-30Not applicableUs51285 0554 02 nlmimage10 d6366b13
SurmontilTablet50 mgOralSanofi Aventis1971-12-312006-07-28Canada
SurmontilCapsule50 mg/1OralTeva Women's Health1990-09-30Not applicableUs51285 0539 02 nlmimage10 d13068d3
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-trimipramineTablet25 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-trimipramineTablet100 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-trimipramineTablet12.5 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-trimipramineTablet50 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-trimipramineCapsule75 mgOralApotex CorporationNot applicableNot applicableCanada
Novo-tripramine Tab 100mg BPTablet100 mgOralNovopharm Limited1991-12-312015-10-26Canada
Novo-tripramine Tab 25mg BPTablet25 mgOralNovopharm Limited1991-12-312015-10-26Canada
Novo-tripramine Tab 50mg BPTablet50 mgOralNovopharm Limited1991-12-312015-10-26Canada
Nu-trimipramine Tab 100mgTablet100 mgOralNu Pharm Inc1993-12-312012-09-04Canada
Nu-trimipramine Tab 12.5mgTablet12.5 mgOralNu Pharm Inc1993-12-312012-09-04Canada
International/Other Brands
Herphonal (Temmler) / Sapilent (ExtractumPharma) / Stangyl (Sanofi-Aventis) / Trimidura (Mylan dura) / Trimineurin (Hexal) / Tripress (Mylan) / Tydamine (Aspen Pharmacare)
Categories
UNII
6S082C9NDT
CAS number
739-71-9
Weight
Average: 294.4338
Monoisotopic: 294.209598842
Chemical Formula
C20H26N2
InChI Key
ZSCDBOWYZJWBIY-UHFFFAOYSA-N
InChI
InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}-2-methylpropyl)dimethylamine
SMILES
CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12

Pharmacology

Indication

For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance

Structured Indications
Pharmacodynamics

Trimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.

Mechanism of action

Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
USodium-dependent dopamine transporter
inhibitor
Human
U5-hydroxytryptamine receptor 2A
agonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UD(2) dopamine receptor
other/unknown
Human
UAlpha-2B adrenergic receptor
other/unknown
Human
UHistamine H1 receptor
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 3A
binder
Human
U5-hydroxytryptamine receptor 1D
binder
Human
UAlpha-2A adrenergic receptor
desensitize the target
Human
UD(1) dopamine receptor
binder
Human
UBeta adrenergic receptor
binder
Human
UMuscarinic acetylcholine receptor
binder
Human
U5-hydroxytryptamine receptor 1C
binder
Rat
Absorption

Rapid absorption

Volume of distribution
Not Available
Protein binding

93%-96% (to plasma proteins)

Metabolism

Hepatic

Route of elimination
Not Available
Half life

11-18 hrs

Clearance
Not Available
Toxicity

Side effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2C19CYP2C19*2Not Available681G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Trimipramine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineTrimipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineTrimipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-DichloroisocoumarinThe serum concentration of Trimipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineTrimipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Trimipramine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineTrimipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineTrimipramine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Trimipramine.Experimental
AbirateroneThe serum concentration of Trimipramine can be increased when it is combined with Abiraterone.Approved
AcenocoumarolTrimipramine may increase the anticoagulant activities of Acenocoumarol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Trimipramine.Approved
AgmatineTrimipramine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AlogliptinThe serum concentration of Trimipramine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Trimipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AltretamineAltretamine may increase the orthostatic hypotensive activities of Trimipramine.Approved
AmiodaroneThe metabolism of Trimipramine can be decreased when combined with Amiodarone.Approved, Investigational
AmobarbitalThe metabolism of Trimipramine can be increased when combined with Amobarbital.Approved, Illicit
AmphetamineTrimipramine may increase the stimulatory activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Trimipramine can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Trimipramine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Trimipramine can be increased when it is combined with Apixaban.Approved
ApomorphineTrimipramine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineTrimipramine may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Trimipramine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Trimipramine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Trimipramine can be increased when it is combined with Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Trimipramine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Trimipramine can be decreased when combined with Artemether.Approved
AsunaprevirThe serum concentration of Trimipramine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Trimipramine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Trimipramine can be decreased when combined with Atomoxetine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Trimipramine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Trimipramine can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Trimipramine can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Trimipramine can be increased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Trimipramine can be increased when it is combined with Benzamidine.Experimental
BenzphetamineTrimipramine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
BetaxololThe metabolism of Trimipramine can be decreased when combined with Betaxolol.Approved
BethanidineTrimipramine may decrease the antihypertensive activities of Bethanidine.Approved
BivalirudinThe serum concentration of Trimipramine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Trimipramine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Trimipramine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Trimipramine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Trimipramine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trimipramine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Trimipramine.Experimental
BromocriptineTrimipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BupropionThe metabolism of Trimipramine can be decreased when combined with Bupropion.Approved
CamostatThe serum concentration of Trimipramine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Trimipramine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Trimipramine can be increased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Trimipramine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Trimipramine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Trimipramine can be increased when combined with Carbamazepine.Approved, Investigational
CelecoxibThe metabolism of Trimipramine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Trimipramine is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Trimipramine can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Trimipramine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Trimipramine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphentermineTrimipramine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Trimipramine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Trimipramine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Trimipramine can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Trimipramine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Trimipramine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Trimipramine can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Trimipramine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Trimipramine can be increased when it is combined with Cinacalcet.Approved
CirazolineTrimipramine may increase the vasopressor activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Trimipramine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Trimipramine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClobazamThe metabolism of Trimipramine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Trimipramine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineTrimipramine may decrease the antihypertensive activities of Clonidine.Approved
ClorindioneTrimipramine may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Trimipramine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Trimipramine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Trimipramine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Trimipramine can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Trimipramine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Trimipramine.Approved, Investigational
CrisaboroleThe metabolism of Trimipramine can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Trimipramine can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Trimipramine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trimipramine.Approved
DabrafenibThe serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trimipramine.Investigational
DarexabanThe serum concentration of Trimipramine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Trimipramine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Trimipramine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Trimipramine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Trimipramine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Trimipramine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Trimipramine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Trimipramine can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Trimipramine can be decreased when combined with Desipramine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.Approved
DexmedetomidineTrimipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Trimipramine.Approved
DextroamphetamineTrimipramine may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DicoumarolTrimipramine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionTrimipramine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DihydroergotamineTrimipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DiltiazemThe metabolism of Trimipramine can be decreased when combined with Diltiazem.Approved
DiphenadioneTrimipramine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Trimipramine can be decreased when combined with Diphenhydramine.Approved
DipivefrinTrimipramine may decrease the antihypertensive activities of Dipivefrin.Approved
DobutamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dobutamine.Approved
DosulepinThe metabolism of Trimipramine can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Trimipramine.Approved, Investigational
DoxycyclineThe metabolism of Trimipramine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Trimipramine can be decreased when combined with Dronedarone.Approved
DroxidopaTrimipramine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Trimipramine.Approved
EcabetThe serum concentration of Trimipramine can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Trimipramine.Approved
EfavirenzThe metabolism of Trimipramine can be decreased when combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Trimipramine can be increased when it is combined with Elafin.Investigational
EliglustatThe metabolism of Trimipramine can be decreased when combined with Eliglustat.Approved
EnalaprilThe serum concentration of Trimipramine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Trimipramine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Trimipramine can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Trimipramine can be decreased when it is combined with Enzalutamide.Approved
EphedraTrimipramine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Trimipramine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinephrineTrimipramine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgotamineTrimipramine may decrease the antihypertensive activities of Ergotamine.Approved
ErythromycinThe metabolism of Trimipramine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Trimipramine can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Trimipramine can be decreased when combined with Esomeprazole.Approved, Investigational
Ethyl biscoumacetateTrimipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtomidateTrimipramine may decrease the antihypertensive activities of Etomidate.Approved
EtravirineThe metabolism of Trimipramine can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Trimipramine.Approved
FaldaprevirThe serum concentration of Trimipramine can be increased when it is combined with Faldaprevir.Investigational
FenoterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fenoterol.Approved, Investigational
FloxuridineThe metabolism of Trimipramine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Trimipramine can be decreased when combined with Fluconazole.Approved
FluindioneTrimipramine may increase the anticoagulant activities of Fluindione.Investigational
FluorouracilThe metabolism of Trimipramine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Trimipramine.Approved, Vet Approved
FluvastatinThe metabolism of Trimipramine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trimipramine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Trimipramine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Trimipramine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Trimipramine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Trimipramine can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the serotonergic activities of Trimipramine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Trimipramine can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Trimipramine can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Trimipramine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Trimipramine can be decreased when combined with Gemfibrozil.Approved
GepefrineTrimipramine may increase the stimulatory activities of Gepefrine.Experimental
GM6001The serum concentration of Trimipramine can be increased when it is combined with GM6001.Experimental
GuanabenzTrimipramine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineTrimipramine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HaloperidolThe metabolism of Trimipramine can be decreased when combined with Haloperidol.Approved
HarmalineHarmaline may increase the serotonergic activities of Trimipramine.Experimental
HexobarbitalThe metabolism of Trimipramine can be increased when combined with Hexobarbital.Approved
HydroxyamphetamineTrimipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved
IdelalisibThe metabolism of Trimipramine can be decreased when combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Trimipramine can be increased when it is combined with Idraparinux.Investigational
ImatinibThe metabolism of Trimipramine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Trimipramine can be increased when it is combined with Imidapril.Investigational
ImipramineThe metabolism of Trimipramine can be decreased when combined with Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indacaterol.Approved
IndinavirThe metabolism of Trimipramine can be decreased when combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Trimipramine.Approved, Investigational
Iofetamine I-123Trimipramine may increase the stimulatory activities of Iofetamine I-123.Approved
IproniazidIproniazid may increase the serotonergic activities of Trimipramine.Withdrawn
IrbesartanThe metabolism of Trimipramine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Trimipramine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoetarineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isoetarine.Approved
IsoflurophateThe serum concentration of Trimipramine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Trimipramine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isoprenaline.Approved
IsradipineThe metabolism of Trimipramine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Trimipramine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Trimipramine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Trimipramine can be increased when it is combined with Ixazomib.Approved
KetoconazoleThe metabolism of Trimipramine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Trimipramine.Approved, Nutraceutical, Withdrawn
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Trimipramine.Approved
LeflunomideThe metabolism of Trimipramine can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinThe serum concentration of Trimipramine can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Trimipramine can be increased when it is combined with Letaxaban.Investigational
LevonordefrinTrimipramine may decrease the antihypertensive activities of Levonordefrin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levosalbutamol.Approved
LinagliptinThe serum concentration of Trimipramine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Trimipramine.Approved, Investigational
LisdexamfetamineTrimipramine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Trimipramine can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Trimipramine.Approved
LobeglitazoneThe metabolism of Trimipramine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineTrimipramine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Trimipramine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Trimipramine can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Trimipramine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Trimipramine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Trimipramine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Trimipramine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Trimipramine can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Trimipramine can be decreased when combined with Manidipine.Approved, Investigational
MelagatranThe serum concentration of Trimipramine can be increased when it is combined with Melagatran.Experimental
MephedroneTrimipramine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineTrimipramine may increase the vasopressor activities of Mephentermine.Approved
MetaraminolTrimipramine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MethadoneThe metabolism of Trimipramine can be decreased when combined with Methadone.Approved
MethamphetamineTrimipramine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethohexitalThe metabolism of Trimipramine can be increased when combined with Methohexital.Approved
MethotrimeprazineThe metabolism of Trimipramine can be decreased when combined with Methotrimeprazine.Approved
MethoxamineTrimipramine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyphenamineTrimipramine may increase the stimulatory activities of Methoxyphenamine.Experimental
Methylene blueTrimipramine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.Approved, Investigational
MethylphenobarbitalThe metabolism of Trimipramine can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimipramine.Approved, Investigational
MetoprololThe metabolism of Trimipramine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Trimipramine.Approved
MidodrineTrimipramine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineTrimipramine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Trimipramine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Trimipramine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Trimipramine.Approved
MirabegronThe metabolism of Trimipramine can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Trimipramine can be decreased when it is combined with Mitotane.Approved
MMDATrimipramine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Trimipramine can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Trimipramine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Trimipramine can be increased when it is combined with Moexipril.Approved
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Trimipramine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Trimipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Trimipramine can be increased when it is combined with Nafamostat.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Trimipramine.Approved
NaphazolineTrimipramine may decrease the antihypertensive activities of Naphazoline.Approved
NefazodoneThe metabolism of Trimipramine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Trimipramine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Trimipramine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Trimipramine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Trimipramine.Withdrawn
NicardipineThe metabolism of Trimipramine can be decreased when combined with Nicardipine.Approved
NicorandilTrimipramine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NilotinibThe metabolism of Trimipramine can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinThe serum concentration of Trimipramine can be increased when it is combined with Nitroaspirin.Investigational
NorepinephrineTrimipramine may decrease the antihypertensive activities of Norepinephrine.Approved
OlaparibThe metabolism of Trimipramine can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olodaterol.Approved
OmapatrilatThe serum concentration of Trimipramine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Trimipramine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Orciprenaline.Approved
OsimertinibThe serum concentration of Trimipramine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Trimipramine can be increased when it is combined with Otamixaban.Investigational
OxymetazolineTrimipramine may decrease the antihypertensive activities of Oxymetazoline.Approved
PalbociclibThe serum concentration of Trimipramine can be increased when it is combined with Palbociclib.Approved
PaliperidoneTrimipramine may decrease the antihypertensive activities of Paliperidone.Approved
PanobinostatThe serum concentration of Trimipramine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Trimipramine can be decreased when combined with Pantoprazole.Approved
PargylinePargyline may increase the serotonergic activities of Trimipramine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Trimipramine.Approved
Peginterferon alfa-2bThe serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Trimipramine can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideTrimipramine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Trimipramine can be increased when it is combined with Perindopril.Approved
PhenindioneTrimipramine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Trimipramine can be increased when combined with Phenobarbital.Approved
PhenprocoumonTrimipramine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineTrimipramine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineTrimipramine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Trimipramine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Trimipramine can be increased when it is combined with Phosphoramidon.Experimental
PirbuterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pirbuterol.Approved
PirlindolePirlindole may increase the serotonergic activities of Trimipramine.Approved
PosaconazoleThe metabolism of Trimipramine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Trimipramine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Trimipramine can be increased when it is combined with Prinomastat.Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Procaterol.Approved, Investigational
PromazineThe metabolism of Trimipramine can be decreased when combined with Promazine.Approved, Vet Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Trimipramine.Approved
PseudoephedrineTrimipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
PyrimethamineThe metabolism of Trimipramine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe serum concentration of Trimipramine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineTrimipramine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe metabolism of Trimipramine can be decreased when combined with Quinine.Approved
RacecadotrilThe serum concentration of Trimipramine can be increased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Trimipramine can be increased when it is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Trimipramine.Approved, Investigational
RemikirenThe serum concentration of Trimipramine can be increased when it is combined with Remikiren.Approved
RifabutinThe metabolism of Trimipramine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Trimipramine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Trimipramine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Trimipramine.Approved, Investigational
RisperidoneTrimipramine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronTrimipramine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Trimipramine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Trimipramine can be increased when it is combined with Rivaroxaban.Approved
RolapitantThe metabolism of Trimipramine can be decreased when combined with Rolapitant.Approved
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Trimipramine.Approved, Investigational
RucaparibThe metabolism of Trimipramine can be decreased when combined with Rucaparib.Approved, Investigational
S-3304The serum concentration of Trimipramine can be increased when it is combined with S-3304.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Salmeterol.Approved
SaquinavirThe metabolism of Trimipramine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Trimipramine can be decreased when used in combination with Sarilumab.Approved
SaxagliptinThe serum concentration of Trimipramine can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Trimipramine can be increased when combined with Secobarbital.Approved, Vet Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Trimipramine.Approved
SildenafilThe metabolism of Trimipramine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Trimipramine.Approved
SiltuximabThe serum concentration of Trimipramine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Trimipramine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Trimipramine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Trimipramine can be increased when it is combined with Sivelestat.Investigational
Sodium phosphateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sodium phosphate.Approved
SorafenibThe metabolism of Trimipramine can be decreased when combined with Sorafenib.Approved, Investigational
SpiraprilThe serum concentration of Trimipramine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Trimipramine can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Trimipramine can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Trimipramine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Trimipramine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Trimipramine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe metabolism of Trimipramine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Trimipramine can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Trimipramine can be increased when it is combined with Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Trimipramine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Terbutaline.Approved
ThiamylalThe metabolism of Trimipramine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Trimipramine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Trimipramine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiorphanThe serum concentration of Trimipramine can be increased when it is combined with Thiorphan.Experimental
TicagrelorThe metabolism of Trimipramine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Trimipramine can be decreased when combined with Ticlopidine.Approved
TioclomarolTrimipramine may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Trimipramine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTrimipramine may decrease the antihypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Trimipramine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Trimipramine can be decreased when combined with Tolbutamide.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Trimipramine.Approved
TopiramateThe metabolism of Trimipramine can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Trimipramine can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Trimipramine.Approved, Investigational
TramadolTrimipramine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Trimipramine can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Trimipramine can be decreased when combined with Tranylcypromine.Approved
TrimethoprimThe metabolism of Trimipramine can be decreased when combined with Trimethoprim.Approved, Vet Approved
UbenimexThe serum concentration of Trimipramine can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Trimipramine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Trimipramine can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Trimipramine can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Trimipramine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Trimipramine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Trimipramine can be decreased when combined with Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vilanterol.Approved
VildagliptinThe serum concentration of Trimipramine can be increased when it is combined with Vildagliptin.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Trimipramine.Approved, Investigational
VoriconazoleThe metabolism of Trimipramine can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinTrimipramine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Trimipramine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineTrimipramine may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Trimipramine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Trimipramine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Trimipramine can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Trimipramine can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Trimipramine can be increased when it is combined with Zofenopril.Experimental
ZucapsaicinThe metabolism of Trimipramine can be decreased when combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14864
KEGG Drug
D00394
PubChem Compound
5584
PubChem Substance
46507121
ChemSpider
5382
BindingDB
50240410
ChEBI
9738
ChEMBL
CHEMBL644
Therapeutic Targets Database
DAP001153
PharmGKB
PA451791
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Trimipramine
ATC Codes
N06AA06 — Trimipramine
AHFS Codes
  • 28:16.04.28 — Tricyclics and Other Norepinephrine-reuptake Inhibitors
FDA label
Download (152 KB)
MSDS
Download (75 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4Unknown StatusNot AvailableMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral75 mg
TabletOral100 mg
TabletOral12.5 mg
TabletOral25 mg
TabletOral50 mg
CapsuleOral100 mg/1
CapsuleOral25 mg/1
CapsuleOral50 mg/1
Prices
Unit descriptionCostUnit
Trimipramine maleate powder51.0USD g
Surmontil 100 mg capsule5.92USD capsule
Surmontil 50 mg capsule4.15USD capsule
Trimipramine Maleate 50 mg capsule3.27USD capsule
Trimipramine 50 mg capsule3.14USD capsule
Surmontil 25 mg capsule2.49USD capsule
Trimipramine 25 mg capsule1.92USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)45 °CPhysProp
water solubilitySlightly solubleNot Available
logP4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.026 mg/mLALOGPS
logP4.67ALOGPS
logP4.76ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.02 m3·mol-1ChemAxon
Polarizability35.67 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9739
Blood Brain Barrier+0.9861
Caco-2 permeable+0.8059
P-glycoprotein substrateSubstrate0.6559
P-glycoprotein inhibitor IInhibitor0.8838
P-glycoprotein inhibitor IIInhibitor0.8826
Renal organic cation transporterInhibitor0.7098
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6698
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9094
CYP450 3A4 inhibitorNon-inhibitor0.6132
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6083
Ames testNon AMES toxic0.8109
CarcinogenicityNon-carcinogens0.9021
BiodegradationNot ready biodegradable0.9886
Rat acute toxicity2.8709 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9065
hERG inhibition (predictor II)Inhibitor0.8271
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4m-5790000000-53c724efbeeb45818f39
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-68bace4e48742b76d7b4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0090000000-683044c8af33df070967
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-1960000000-2c69c2591b0ff915ccc2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-3920000000-7c68e89e7f53026fdb80
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-4930000000-f1fe2a4f61bfbec6d778
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-7920000000-b085a14dd7e5d88d4922
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-9810000000-b67a0e6866c4bcb27488
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0090000000-90da643ba602b4854ad4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-1960000000-953dd8f5d50ce412ae55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-2920000000-493d39be6384cb3b09d4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-4920000000-02c877be6bc360fbe70e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-6920000000-eb3878e47d12e4792744
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-8910000000-5341bd1feea3e6a75bc8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-875e7a40df38e129227c

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Dibenzazepines
Direct Parent
Dibenzazepines
Alternative Parents
Alkyldiarylamines / Azepines / Benzenoids / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzazepine / Alkyldiarylamine / Tertiary aliphatic/aromatic amine / Azepine / Benzenoid / Tertiary aliphatic amine / Tertiary amine / Azacycle / Organic nitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, dibenzoazepine (CHEBI:9738)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Diamond M, Kelly JP, Connor TJ: Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. Epub 2006 Jan 4. [PubMed:16388933]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Details
10. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Desensitize the target
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...

Components:
References
  1. Eikmeier G, Muszynski K, Berger M, Gastpar M: High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial. Pharmacopsychiatry. 1990 Sep;23(5):212-4. [PubMed:1979173]
Kind
Protein
Organism
Rat
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
Htr2c
Uniprot ID
P08909
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51916.005 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]

Drug created on June 13, 2005 07:24 / Updated on January 14, 2018 10:04